Innate Pharma S.A. (IPH.PA)
EUR 1.98
(-3.37%)
EUR 1.98
(-3.37%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -7.57 Million EUR | 92.36% |
| 2022 | -99.1 Million EUR | -67.58% |
| 2021 | -59.13 Million EUR | 16.41% |
| 2020 | -70.74 Million EUR | -237.45% |
| 2019 | -20.96 Million EUR | -787.6% |
| 2018 | 3.04 Million EUR | 106.3% |
| 2017 | -48.38 Million EUR | -482.79% |
| 2016 | 12.64 Million EUR | 288.49% |
| 2015 | -6.7 Million EUR | 65.87% |
| 2014 | -19.64 Million EUR | -579.36% |
| 2013 | -2.89 Million EUR | 9.6% |
| 2012 | -3.19 Million EUR | 54.17% |
| 2011 | -6.98 Million EUR | 48.89% |
| 2010 | -13.65 Million EUR | 6.62% |
| 2009 | -14.62 Million EUR | -48.46% |
| 2008 | -9.85 Million EUR | -10.47% |
| 2007 | -8.91 Million EUR | -47.6% |
| 2006 | -6.04 Million EUR | 1.42% |
| 2005 | -6.12 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -12.38 Million EUR | -166.62% |
| 2024 Q2 | -12.38 Million EUR | 0.0% |
| 2023 Q4 | -4.64 Million EUR | 0.0% |
| 2023 Q3 | -4.64 Million EUR | -370.31% |
| 2023 Q1 | 859 Thousand EUR | 101.33% |
| 2023 FY | -7.57 Million EUR | 92.36% |
| 2023 Q2 | 1.71 Million EUR | 100.0% |
| 2022 FY | -99.1 Million EUR | -67.58% |
| 2022 Q1 | 3.18 Million EUR | 110.96% |
| 2022 Q2 | 6.3 Million EUR | 97.71% |
| 2022 Q3 | -32.17 Million EUR | -610.46% |
| 2022 Q4 | -64.4 Million EUR | -100.18% |
| 2021 Q1 | -8.73 Million EUR | 83.72% |
| 2021 FY | -59.13 Million EUR | 16.41% |
| 2021 Q3 | -14 Million EUR | 40.96% |
| 2021 Q2 | -23.71 Million EUR | -171.54% |
| 2021 Q4 | -29.09 Million EUR | -107.73% |
| 2020 FY | -70.74 Million EUR | -237.45% |
| 2020 Q1 | -5.16 Million EUR | 84.8% |
| 2020 Q4 | -53.65 Million EUR | -100.0% |
| 2020 Q3 | -26.82 Million EUR | -159.58% |
| 2020 Q2 | -10.33 Million EUR | -100.0% |
| 2019 Q2 | 13.24 Million EUR | 100.0% |
| 2019 Q3 | -16.99 Million EUR | -228.4% |
| 2019 Q4 | -33.99 Million EUR | -100.0% |
| 2019 FY | -20.96 Million EUR | -787.6% |
| 2019 Q1 | 6.62 Million EUR | -27.12% |
| 2018 Q1 | -7.55 Million EUR | 39.59% |
| 2018 FY | 3.04 Million EUR | 106.3% |
| 2018 Q4 | 9.08 Million EUR | 0.0% |
| 2018 Q3 | 9.08 Million EUR | 220.17% |
| 2018 Q2 | -7.55 Million EUR | 0.0% |
| 2017 Q1 | -11.67 Million EUR | -247.74% |
| 2017 FY | -48.38 Million EUR | -482.79% |
| 2017 Q4 | -12.51 Million EUR | 0.0% |
| 2017 Q3 | -12.51 Million EUR | -7.14% |
| 2017 Q2 | -11.67 Million EUR | 0.0% |
| 2016 Q2 | -1.58 Million EUR | 0.0% |
| 2016 FY | 12.64 Million EUR | 288.49% |
| 2016 Q4 | 7.9 Million EUR | 0.0% |
| 2016 Q3 | 7.9 Million EUR | 598.61% |
| 2016 Q1 | -1.58 Million EUR | -340.23% |
| 2015 Q1 | -4.01 Million EUR | 24.34% |
| 2015 FY | -6.7 Million EUR | 65.87% |
| 2015 Q2 | -4.01 Million EUR | 0.0% |
| 2015 Q4 | 660 Thousand EUR | 0.0% |
| 2015 Q3 | 660 Thousand EUR | 116.45% |
| 2014 Q3 | -5.3 Million EUR | -17.36% |
| 2014 Q1 | -4.51 Million EUR | -1488.58% |
| 2014 Q2 | -4.51 Million EUR | 0.0% |
| 2014 Q4 | -5.3 Million EUR | 0.0% |
| 2014 FY | -19.64 Million EUR | -579.36% |
| 2013 Q3 | -284.5 Thousand EUR | 75.51% |
| 2013 Q1 | -1.16 Million EUR | -97.2% |
| 2013 FY | -2.89 Million EUR | 9.6% |
| 2013 Q4 | -284.5 Thousand EUR | 0.0% |
| 2013 Q2 | -1.16 Million EUR | 0.0% |
| 2012 Q4 | -589 Thousand EUR | 0.0% |
| 2012 FY | -3.19 Million EUR | 54.17% |
| 2012 Q3 | -589 Thousand EUR | 0.0% |
| 2011 FY | -6.98 Million EUR | 48.89% |
| 2010 FY | -13.65 Million EUR | 6.62% |
| 2009 FY | -14.62 Million EUR | -48.46% |
| 2008 FY | -9.85 Million EUR | -10.47% |
| 2007 FY | -8.91 Million EUR | -47.6% |
| 2006 FY | -6.04 Million EUR | 1.42% |
| 2005 FY | -6.12 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -115.179% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 94.876% |
| Adocia SA | -21.16 Million EUR | 64.228% |
| Aelis Farma SA | -5.07 Million EUR | -49.074% |
| Biophytis S.A. | -17.02 Million EUR | 55.539% |
| Advicenne S.A. | -7.03 Million EUR | -7.666% |
| genOway Société anonyme | 1.56 Million EUR | 582.912% |
| IntegraGen SA | -171.39 Thousand EUR | -4316.595% |
| Medesis Pharma S.A. | -3.95 Million EUR | -91.186% |
| Neovacs S.A. | -8.74 Million EUR | 13.421% |
| NFL Biosciences SA | -3.74 Million EUR | -102.11% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 9661.823% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -138.73% |
| Sensorion SA | -22.06 Million EUR | 65.69% |
| Theranexus Société Anonyme | -6.82 Million EUR | -10.868% |
| TME Pharma N.V. | -6.73 Million EUR | -12.381% |
| Valbiotis SA | -7.36 Million EUR | -2.742% |
| TheraVet SA | -1.57 Million EUR | -381.949% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | 62.79% |
| argenx SE | -272.91 Million EUR | 97.226% |
| BioSenic S.A. | -28.77 Million EUR | 73.695% |
| Celyad Oncology SA | -8.44 Million EUR | 10.393% |
| DBV Technologies S.A. | -67.26 Million EUR | 88.747% |
| Galapagos NV | 211.69 Million EUR | 103.576% |
| Genfit S.A. | -28.89 Million EUR | 73.801% |
| GeNeuro SA | -14.75 Million EUR | 48.702% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | 50.78% |
| Inventiva S.A. | -110.42 Million EUR | 93.145% |
| MaaT Pharma SA | -19.71 Million EUR | 61.607% |
| MedinCell S.A. | -25.03 Million EUR | 69.766% |
| Nanobiotix S.A. | -39.7 Million EUR | 80.932% |
| Onward Medical N.V. | -36.18 Million EUR | 79.077% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -125.772% |
| OSE Immunotherapeutics SA | -23 Million EUR | 67.091% |
| Oxurion NV | -18.96 Million EUR | 60.093% |
| Pharming Group N.V. | -9.75 Million EUR | 22.411% |
| Poxel S.A. | -35.09 Million EUR | 78.427% |
| GenSight Biologics S.A. | -26.22 Million EUR | 71.129% |
| Transgene SA | -22.32 Million EUR | 66.096% |
| Financière de Tubize SA | 88.15 Million EUR | 108.588% |
| UCB SA | 343 Million EUR | 102.207% |
| Valneva SE | -101.42 Million EUR | 92.537% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 73.291% |